RESUMEN
The authors summarize clinical evidence obtained on the efficacy of a new Russian cryoprotector hecmolit in the conduction of autotransplantation of 8 patients with acute leukemia. The markers of the preserved hemopoietic potential of the unfrozen bone marrow were the amount of myelokaryocytes, their viability in the test with vital stain, CFU-GM level. Infusions of the marrow suspension incorporating hecmolit (120-180 ml) produced minimaL side effects. After thawing myelokaryocytes remained in the amount 81.7 +/- 8.2% or 1.6 +/- 0.4 x 10(8) cell / kg, on the average. Estimation of the aggregates in terms of the weight revealed that hemopoietic potential was sufficient for the transplant survival (2.9 +/- 0.7 x 10(3) CFU-GM/kg) though only 50 +/- 10% of CFU-GM remained safe. Hecmolit tolerance was satisfactory. The preparation is thought convenient for bone marrow transplantation practice.